Brain-computer interface Metanalysis Amyotrophic lateral sclerosis Locked-in syndrome h i g h l i g h t s
h i g h l i g h t s
Amyotrophic lateral sclerosis (ALS) patients might communicate through brain-computer interfaces (BCI). We metanalyzed all relevant studies on BCI efficacy. There is limited evidence of BCI efficacy in ALS patients.
a b s t r a c t
Objective: Despite recent groundbreaking findings on the genetic causes of amyotrophic lateral sclerosis (ALS), and improvements on neuroimaging techniques for ALS diagnosis have been reported, the main clinical intervention in ALS remains palliative care. Brain-computer interfaces (BCIs) have been proposed as a channel of communication and control for ALS patients. The present metanalysis was performed to test the evidence of BCI effectiveness in ALS, and to investigate whether the promising aims emerged from the first studies have been reached. Methods: Studies on ALS patients tested with BCIs, until June 2013, were searched in PubMed and PsychInfo. The random-effect approach was used to compute the pooled effectiveness of BCI in ALS. A meta-regression was performed to test whether there was a BCI performance improvement as a function of time. Finally, BCI effectiveness for complete paralyzed ALS patients was tested. Twenty-seven studies were eligible for metanalysis. Results: The pooled classification accuracy (C.A.) of ALS patients with BCI was about 70%, but this estimation was affected by significant heterogeneity and inconsistency. C.A. did not significantly increase as a function of time. C.A. of completely paralyzed ALS patients with BCI did not differ from that obtained by chance. Conclusions: After 15 years of studies, it is as yet not possible to reliably establish the effectiveness of BCIs. Significance: Methodological issues among the retrieved studies should be addressed and new well-powered studies should be conducted to confirm BCI effectiveness for ALS patients. Ó 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
Introduction
In the second half of the 19th century, Jean-Martin Charcot described a new ''progressive atrophy invading the muscles' ' (Goetz, 2000) . Thanks to his ''method anatomoclinique'', Charcot associated the signs of the abovementioned neuromuscular disease with distinct, white and grey matter lesions, in specific sites of the central nervous system. Indeed, Charcot was the first to diagnose a case of amyotrophic lateral sclerosis (ALS; Charcot and Joffroy, 1869). Progressively, ALS brings the affected patients to lose the ability of voluntarily initiating and controlling their movements. ALS results in death, on average, within 2-5 years from onset, with some exceptions of patients that can survive for more than 10 years (Testa et al., 2004) . The first cause of death in ALS is respiratory failure (Radunovic et al., 2013 
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